Demographic and Clinical Characteristics
The patients’ unadjusted characteristics are summarized in Supplementary
Tables S5-S8. Compared with warfarin users, rivaroxaban 15 mg users were
lightly younger (mean ± standard deviation [SD] age: 83.0 ± 8.5 vs.
82.6 ± 7.8, respectively) and had a lower mean ± SD Charlson-Deyo
Comorbidity Index (6.1 ± 3.4 vs. 5.3 ± 3.5, respectively), a lower mean
± SD CHADS2 score (3.1 ± 1.2 vs. 2.8 ± 1.2,
respectively) and a lower mean ± SD HAS-BLED score (3.6 ± 1.3 vs. 3.2 ±
1.3, respectively). Compared with warfarin users, rivaroxaban 20 mg
users were younger (mean ± SD age: 83.0 ± 8.5 vs. 74.2 ± 9.2,
respectively) and had a lower mean ± SD Charlson-Deyo Comorbidity Index
(6.1 ± 3.4 vs. 4.7 ± 3.5, respectively), a lower mean ± SD
CHADS2 score (3.1 ± 1.2 vs. 2.3 ± 1.2, respectively) and
a lower mean ± SD HAS-BLED score (3.6 ± 1.3 vs. 2.7 ± 1.3,
respectively). Compared with warfarin users, apixaban 2.5 mg users were
older (mean ± SD age: 83.0 ± 8.5 vs. 86.5 ± 6.3, respectively) and had a
lower mean ± SD Charlson-Deyo Comorbidity Index (6.1 ± 3.4 vs. 5.4 ±
3.3, respectively), a similar mean ± SD CHADS2 score
(3.1 ± 1.2 vs. 3.0 ± 1.1, respectively) and a similar mean ± SD HAS-BLED
score (3.6 ± 1.3 vs. 3.3 ± 1.3, respectively). And, compared with
warfarin users, apixaban 5.0 mg users were also younger (mean ± SD age:
83.0 ± 8.5 vs. 78.0 ± 8.4, respectively) and had a lower mean ± SD
Charlson-Deyo Comorbidity Index (6.1 ± 3.4 vs. 5.1 ± 3.5, respectively),
a lower mean ± SD CHADS2 score (3.1 ± 1.2 vs. 2.6 ± 1.2,
respectively) and a lower mean ± SD HAS-BLED score (3.6 ± 1.3 vs. 3.0 ±
1.3, respectively). As shown in Table 1, demographic and clinical
characteristics of cohorts of new OAC users with stage III CKD after
IPTW from 2013 to 2017 are well balanced.